全文获取类型
收费全文 | 46651篇 |
免费 | 3829篇 |
国内免费 | 137篇 |
专业分类
耳鼻咽喉 | 610篇 |
儿科学 | 1170篇 |
妇产科学 | 619篇 |
基础医学 | 5886篇 |
口腔科学 | 504篇 |
临床医学 | 4899篇 |
内科学 | 9331篇 |
皮肤病学 | 517篇 |
神经病学 | 4595篇 |
特种医学 | 1814篇 |
外科学 | 8868篇 |
综合类 | 498篇 |
现状与发展 | 1篇 |
一般理论 | 60篇 |
预防医学 | 3907篇 |
眼科学 | 970篇 |
药学 | 3010篇 |
中国医学 | 37篇 |
肿瘤学 | 3321篇 |
出版年
2024年 | 52篇 |
2023年 | 447篇 |
2022年 | 711篇 |
2021年 | 2089篇 |
2020年 | 1081篇 |
2019年 | 1737篇 |
2018年 | 2084篇 |
2017年 | 1464篇 |
2016年 | 1485篇 |
2015年 | 1638篇 |
2014年 | 2369篇 |
2013年 | 2798篇 |
2012年 | 4407篇 |
2011年 | 4312篇 |
2010年 | 2266篇 |
2009年 | 1903篇 |
2008年 | 3029篇 |
2007年 | 3140篇 |
2006年 | 2628篇 |
2005年 | 2354篇 |
2004年 | 2075篇 |
2003年 | 1761篇 |
2002年 | 1526篇 |
2001年 | 201篇 |
2000年 | 201篇 |
1999年 | 224篇 |
1998年 | 282篇 |
1997年 | 224篇 |
1996年 | 162篇 |
1995年 | 140篇 |
1994年 | 128篇 |
1993年 | 89篇 |
1992年 | 100篇 |
1991年 | 93篇 |
1990年 | 81篇 |
1989年 | 87篇 |
1988年 | 89篇 |
1987年 | 86篇 |
1986年 | 84篇 |
1985年 | 82篇 |
1984年 | 67篇 |
1983年 | 64篇 |
1982年 | 66篇 |
1981年 | 45篇 |
1980年 | 54篇 |
1979年 | 62篇 |
1978年 | 48篇 |
1976年 | 59篇 |
1975年 | 40篇 |
1974年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
71.
Image processing is a critical part of obtaining high-quality digital radiographs. Fortunately, the user of these systems does not need to understand image processing in detail, because the manufacturers provide good starting values. Because radiologists may have different preferences in image appearance, it is helpful to know that many aspects of image appearance can be changed by image processing, and a new preferred setting can be loaded into the computer and saved so that it can become the new standard processing method.Image processing allows one to change the overall optical density of an image and to change its contrast. Spatial frequency processing allows an image to be sharpened, improving its appearance. It also allows noise to be blurred so that it is less visible. Care is necessary to avoid the introduction of artifacts or the hiding of mediastinal tubes. 相似文献
72.
Digital mammography using storage phosphor CR is still in the investigational stage. It is the only digital mammography system that has been tested in preliminary clinical trials with promising early results. Further clinical studies are needed to assess the impact of the limited spatial resolution of storage phosphor technology on its application as a digital screening mammography system. Further studies also are needed to determine the optimum image processing parameters needed in digital mammography. 相似文献
73.
Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy 总被引:5,自引:3,他引:2
下载免费PDF全文
![点击此处可从《Canadian Medical Association journal》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J M Moutquin P R Garner R F Burrows E Rey M E Helewa I R Lange S W Rabkin 《Canadian Medical Association journal》1997,157(7):907-919
OBJECTIVE: To provide Canadian physicians with comprehensive, evidence-based guidelines for the nonpharmacologic management and prevention of gestational hypertension and pre-existing hypertension during pregnancy. OPTIONS: Lifestyle modifications, dietary or nutrient interventions, plasma volume expansion and use of prostaglandin precursors or inhibitors. OUTCOMES: In gestational hypertension, prevention of complications and death related to either its occurrence (primary or secondary prevention) or its severity (tertiary prevention). In pre-existing hypertension, prevention of superimposed gestational hypertension and intrauterine growth retardation. EVIDENCE: Articles retrieved from the pregnancy and childbirth module of the Cochrane Database of Systematic Reviews; pertinent articles published from 1966 to 1996, retrieved through a MEDLINE search; and review of original randomized trials from 1942 to 1996. If evidence was unavailable, consensus was reached by the members of the consensus panel set up by the Canadian Hypertension Society. VALUES: High priority was given to prevention of adverse maternal and neonatal outcomes in pregnancies with established hypertension and in those at high risk of gestational hypertension through the provision of effective nonpharmacologic management. BENEFITS, HARMS AND COSTS: Reduction in rate of long-term hospital admissions among women with gestational hypertension, with establishment of safe home-care blood pressure monitoring and appropriate rest. Targeting prophylactic interventions in selected high-risk groups may avoid ineffective use in the general population. Cost was not considered. RECOMMENDATION: Nonpharmacologic management should be considered for pregnant women with a systolic blood pressure of 140-150 mm Hg or a diastolic pressure of 90-99 mm Hg, or both, measured in a clinical setting. A short-term hospital stay may be required for diagnosis and for ruling out severe gestational hypertension (preeclampsia). In the latter case, the only effective treatment is delivery. Palliative management, dependent on blood pressure, gestational age and presence of associated maternal and fetal risk factors, includes close supervision, limitation of activities and some bed rest. A normal diet without salt restriction is advised. Promising preventive interventions that may reduce the incidence of gestational hypertension, especially with proteinuria, include calcium supplementation (2 g/d), fish oil supplementation and low-dose acetylsalicylic acid therapy, particularly in women at high risk for early-onset gestational hypertension. Pre-existing hypertension should be managed the same way as before pregnancy. However, additional concerns are the effects on fetal well-being and the worsening of hypertension during the second half of pregnancy. There is, as yet, no treatment that will prevent exacerbation of the condition. VALIDATION: The guidelines share the principles in consensus reports from the US and Australia on the nonpharmacologic management of hypertension in pregnancy. 相似文献
74.
Dr. Sandra S. Garner Pharm.D. Dr. Donald B. Wiest Pharm.D. Mr. J. Warren Bradley R.R.T. 《Pharmacotherapy》1994,14(2):210-214
Study Objective . To determine albuterol delivery by metered-dose inhaler (MDI) in an in vitro pediatric mechanical ventilatory circuit model. The influence of a spacing device, endotracheal tube (ETT) diameter and length, and air humidity was also investigated. Design . An albuterol MDI canister was connected to an AeroVent spacer or Airlife MDI adapter and ETT 4.0, 5.0, or 6.0 mm at commercially available and equal lengths. The ETT tip was attached to an in-line filter holder with a 1-μm type A/E glass fiber filter. Ventilator settings were fractional concentration of inspired oxygen 50%, tidal volume 250 ml, inspiratory:expiratory (I:E) ratio 1:3, rate 25 breaths/minute, temperature 35°C, and a decelerating flow pattern. Ten albuterol canisters were activated two times each (total 2000 μg) into dry (4.0-, 5.0-, and 6.0-mm ETT) and humidified air (4.0- and 6.0-mm ETT) and repeated in triplicate. Percentage MDI output was determined by weighing the filter before and after drug administration (balance sensitivity 10 μg). Significant differences (p≤0.05) among the groups with and without a spacer and in dry and humidified air were determined by ANOVA with Scheffe's multiple comparison test. Multiple regression was used to determine significant associations between ETT diameter and length and delivery. Main Results . With the AeroVent spacer in humidified air, delivery with the 4.0- and 6.0-mm ETT was approximately 2.3% and 5%, respectively. The spacer and dry air significantly improved delivery. Conclusions . In humidified air, the dose of albuterol by MDI with an AeroVent spacer should be doubled for children intubated with 6.0-mm ETT, and four puffs administered for every one puff desired for 4.0-mm ETT. The results of this investigation should prove useful in initial clinical trials of albuterol MDI in ventilator-dependent infants and children. 相似文献
75.
R C Ayres S G Hübscher J Shaw C Garner R Joplin A Williams J M Neuberger 《The Journal of pathology》1991,165(2):153-161
We have produced a range of monoclonal antibodies which stain human intrahepatic bile ducts of different sizes. Amongst 26 monoclonal antibodies produced, five clones reacted specifically with bile ducts of different sizes, of which three have been maintained in culture and their viability following freezing and thawing confirmed. Staining patterns varied between normal adult liver tissue, normal fetal liver tissue and a variety of hepatobiliary diseases. The antibodies provide further evidence of the immunological heterogeneity of the human intrahepatic biliary tree and support the hypothesis that proliferating bile ductules are derived from periseptal hepatocytes. The preparation of the antibodies, their staining reactions in normal adult, normal fetal and a variety of liver diseases are described. 相似文献
76.
77.
Takahisa Okano Matthew D. Horton Gary G. Fermanis David A. Horton 《The Japanese Journal of Thoracic and Cardiovascular Surgery》2005,53(8):437-439
We report a re-do case of severe aortic valve stenosis due to pannus formation 29 years after an aortic Starr-Edwards caged-ball
valve implantation. A huge shelf of calcified and thick pannus tissue below the valve had reduced the already small orifice
by at least a third in surface area. The explanted Starr-Edwards valve revealed no mechanical or structural failure. Early
detection and treatment of pannus outgrowth is essential in order to prevent life-threatening prosthetic valve malfunctions. 相似文献
78.
79.
T Matthew Shields Charles H Hennekens 《Endocrinology & Metabolism Clinics of North America》2004,33(3):577-93, vii
Cardiovascular disease (CVD), which includes myocardial infarction(MI), stroke, and peripheral vascular disease, remains the leading cause of death in the United States and in most developed countries. In the United States today, 25% of patients have metabolic syndrome-including those who have had a prior occlusive vascular disease event, those who are having an acute MI or ischemic stroke, and finally, the largest segment of the population,namely those who have not yet experienced a clinical CVD, but whose risks are substantial (10-year risk 10%). This article reviews the totality of evidence for aspirin in the treatment and prevention of CVD and emphasizes its importance as adjunctive therapy for patients with metabolic syndrome. 相似文献
80.